PMC/PubMed Indexed Articles
Indexed In
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Efficacy of HBVneonatal vaccination, catch-up vaccination and adolescence booster on Chronic HBV infection in rural area of China
World Congress on Hepatitis
July 20-22, 2015 Orlando, Florida, USA
Chunfeng Qu
Posters-Accepted Abstracts: J Liver
Abstract:
Infection with hepatitis B virus (HBV) in infancy or early childhood leads to a high rate of chronic HBV infection that is the main cause of primary liver cancer (PLC) and end-stage cirrhosis in China. Controlling chronic HBV infection through universal neonatal HBV vaccination is instrumental. From Jan 1, 2002 HBV vaccination was integrated the nationwide expanded program of immunization with vaccines provided entirely by the Chinese Government. During the 1980s, we conducted a population-based, cluster-randomized, controlled trial of HBV vaccination in Qidong, China (QHBIS) when HBV vaccine was unavailable to the rural Chinese population. In this study approximately 40000 new borns were randomly assigned to the vaccination group, 40000 newborns were randomly assigned to the control group. In 2000-2001 the participants in the control group received 3-dose catch-up vaccination and the participants in the vaccination group received one-dose booster. We examined the efficacy of neonatal vaccination, catch-up vaccination and adolescence booster on chronic HBV infection. Our study demonstrated that neonatal vaccination has a significantly protection against PLC development and in decreasing the mortality rate of severe end-stage chronic liver diseases in young adults. Catch-up vaccination received at age 10-14 years reduced HbsAg seroprevalence in young adults with roughly 20% efficacy much lower than neonatal vaccination (with 72% efficacy). A total of 9714 fully vaccine-protected children were serologically re-surveyed at adulthood. Fifty-five adults (0.57%) became HBsAg-positive status, suggestion of HBV breakthrough infection. One-dose adolescence booster showed protective to those born to HBsAg-positive mothers after completing the HBV neonatal vaccination series.